Hepatitis B Surface Antigen Decline and Clearance During Long-Term Tenofovir Therapy in Patients Coinfected With HBV and HIV
The Journal of Infectious Diseases, 08/08/2012
Clinical Article
Zoutendijk R et al. – Receipt of TDF therapy by HIV/HBV–coinfected patients for up to 6 years led to a significant decrease in HBsAg in the HBeAg–positive population. HBsAg kinetics early during treatment were predictive of HBsAg seroclearance and correlated with an increased CD4 cell count, underlining the importance of immune restoration in HBV clearance.
